Tyrosine-kinase inhibitors (TKI) in first-line treatment of patients with non-small cell lung cancer (NSCLC) - real life data from the Czech Republic.

J. Skricková (Brno, Czech Republic), R. Chloupková (Brno, Czech Republic), Z. BortlícEk (Brno, Czech Republic), P. Brabec (Brno, Czech Republic), K. Hejduk (Brno, Czech Republic), L. DušEk (Brno, Czech Republic), M. PešEk (Plzen, Czech Republic), V. Kolek (Olomouc, Czech Republic), L. Koubková (Praha, Czech Republic), M. cErnovská (Praha, Czech Republic), F. Salajka (Hradec Králové, Czech Republic), M. Zemanová (Praha, Czech Republic), J. Krejcí (Praha, Czech Republic), H. cOupková (Brno, Czech Republic), M. šAtáNková (Brno, Czech Republic), A. Benejová (Brno, Czech Republic), M. TomíšKová (Brno, Czech Republic), J. Roubec (Ostrava, Czech Republic), I. GrygáRková (Olomouc, Czech Republic), L. Havel (Praha, Czech Republic), M. HrncIarik (Hradec Králové, Czech Republic), P. OpáLka (Praha, Czech Republic)

Source: International Congress 2018 – Lung cancer: personalised medicine
Session: Lung cancer: personalised medicine
Session type: Poster Discussion
Number: 2213
Disease area: Thoracic oncology

Congress or journal article abstractWebcastE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Skricková (Brno, Czech Republic), R. Chloupková (Brno, Czech Republic), Z. BortlícEk (Brno, Czech Republic), P. Brabec (Brno, Czech Republic), K. Hejduk (Brno, Czech Republic), L. DušEk (Brno, Czech Republic), M. PešEk (Plzen, Czech Republic), V. Kolek (Olomouc, Czech Republic), L. Koubková (Praha, Czech Republic), M. cErnovská (Praha, Czech Republic), F. Salajka (Hradec Králové, Czech Republic), M. Zemanová (Praha, Czech Republic), J. Krejcí (Praha, Czech Republic), H. cOupková (Brno, Czech Republic), M. šAtáNková (Brno, Czech Republic), A. Benejová (Brno, Czech Republic), M. TomíšKová (Brno, Czech Republic), J. Roubec (Ostrava, Czech Republic), I. GrygáRková (Olomouc, Czech Republic), L. Havel (Praha, Czech Republic), M. HrncIarik (Hradec Králové, Czech Republic), P. OpáLka (Praha, Czech Republic). Tyrosine-kinase inhibitors (TKI) in first-line treatment of patients with non-small cell lung cancer (NSCLC) - real life data from the Czech Republic.. 2213

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: